Interaction of human serum albumin with the electrophilic metabolite 1- O-gemfibrozll-β-D-glucuronide

Drug Metabolism and Disposition

Volumn 25, Issue 1, 1997, Pages 55-60

  Sallustio, Benedetta C ^a   Fairchild, Barbara A ^b   Pannall, Peter R ^b  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; DIAZEPAM; GEMFIBROZIL; OXYPHENBUTAZONE;

ARTICLE; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DISPOSITION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG PROTEIN BINDING; HUMAN; MOLECULAR INTERACTION; PRIORITY JOURNAL;

ANTILIPEMIC AGENTS; DIAZEPAM; GEMFIBROZIL; GLUCURONATES; HALF-LIFE; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; OXYPHENBUTAZONE; PILOT PROJECTS; PROTEIN BINDING; SERUM ALBUMIN; TIME FACTORS;

EID: 0031012606     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. P. A. Todd and A. Ward: Gemfibrozil: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia. Drugs 36, 314-339 (1988).
2. M. H. Frick, O. Elo, K. Haapa, O. P. Heinonen, P. Heinsalmi. P. Helo et al.: Helsinki heart study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N. Engl. J. Med. 317, 1237-1245 (1987).
3. H. Knauf, E. U. Kolle, and E. Mutschler: Gemfibrozil absorption and elimination in kidney and liver disease. Klin. Wochenschr. 68, 692-698 (1990).
4. A. Nakagawa, A. Shigeta, H. Iwabuchi, M. Horiguchi, K. Nakamura, and H. Takahagi: Simultaneous determination of gemfibrozil and its metabolites in plasma and urine by a fully automated high performance liquid chromatographic system. Biomed. Chromatogr. 5, 68-73 (1991).
5. H. Spahn-Langguth and L. Z. Benet: Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab. Rev. 24, 5-47 (1992).
6. P. C. Smith and C. Wang: Nonenzymic glycation of albumin by acyl glucuronides in vitro. Comparison of reactions with reducing sugars. Biochem. Pharmacol. 44, 1661-1668 (1992).
7. A. Ding, P. Zia-Amirhosseini, A. F. McDonagh, A. L. Burlingame, and L. Z. Benet: Reactivity of tolmetin glucuronide with human serum albumin. Identification of binding sites and mechanisms of reaction by tandem mass spectrometry. Drug Metab. Dispos. 23, 369-376 (1995).
8. S. Mayer, E. Mutschler, L. Z. Benet, and H. Spahn-Langguth: In vitro and in vivo irreversible plasma protein binding of beclobric acid enantiomers. Chirality 5, 120-125 (1993).
9. B. C. Sallustio, K. M. Knights, B. J. Roberts, and R. Zacest: In vivo covalent binding of clofibric acid to human plasma proteins and rat liver proteins. Biochem. Pharmacol. 42, 1421-1425 (1991).
10. G. E. McKinnon and R. G. Dickinson: Covalent binding of diflunisal and probenecid to plasma protein in humans: persistence of the adducts in the circulation. Res. Comm. Chem. Pathol. Pharmacol. 66, 339-354 (1989).
11. R. G. Dickinson, P. V. Baker, and A. R. King: Studies on the reactivity of acyl glucuronides. VII. Salicyl acyl glucuronide reactivity in vitro and covalent binding of salicylic acid to plasma protein of humans taking aspirin. Biochem. Pharmacol. 47, 469-476 (1994).
12. M. L. Hyneck, P. C. Smith, A. Munafo, A. F. McDonagh, and L. Z. Benet: Disposition and irreversible plasma protein binding of tolmetin in humans. Clin. Pharmacol. Ther. 44, 107-114 (1988).
13. P. Zia-Amirhosseini, J. C. Ojingwa, H. Spahn-Langguth, A. F. McDonagh, and L. Z. Benet: Enhanced covalent binding of tolmetin to proteins after multiple dosing. Clin. Pharmacol. Ther. 55, 21-27 (1994).
14. A. M. Williams, S. Worrall, J. De Jersey, and R. G. Dickinson: Studies on the reactivity of acyl glucuronides. III. Glucuronide-derived adducts of valproic acid and plasma protein and anti-adduct antibodies in humans. Biochem. Pharmacol. 43, 745-755 (1992).
15. P. C. Smith, A. F. McDonagh, and L. Z. Benet: Irreversible binding of zomepirac to plasma protein in vitro and in vivo. J. Clin. Invest. 77, 934-939 (1986).
16. F. Herve, S. Urien, E. Albengres, J.-C. Duche, and J.-P. Tillement: Drug binding in plasma. A summary of recent trends in the study of drug and hormone binding. Clin. Pharmacokinet. 26, 44-58 (1994).
17. D. S. Wells, F. W. Janssen, and H. W. Ruelius: Interactions between oxaprozin glucuronide and human serum albumin. Xenobiotica 17, 1437-1449 (1987).
18. S. Iwakawa, H. Spahn, L. Z. Benet, and E. T. Lin: Stereoselective binding of the glucuronide conjugates of carprofen enantiomers to human serum albumin. Biochem. Pharmacol. 39, 949-953 (1990).
19. J. A. Watt and R. G. Dickinson: Reactivity of diflunisal acyl glucuronide in human and rat plasma and albumin solutions. Biochem. Pharmacol. 39, 1067-1075 (1990).
20. A. M. Williams and R. G. Dickinson: Studies on the reactivity of acyl glucuronides. VI. Modulation of reversible and covalent interaction of diflunisal acyl glucuronide and its isomers with human plasma protein in vitro. Biochem. Pharmacol. 47, 457-467 (1994).
21. P. J. Hayball, R. L. Nation, and F. Bochner: Stereoselective interactions of ketoprofen glucuronides with human plasma proteins and serum albumin. Biochem. Pharmacol. 44, 291-299 (1992).
22. N. Dubois, F. Lapicque, J. Magdalou, M. Abiteboul, and P. Netter: Stereoselective binding of the glucuronide of ketoprofen enantiomers to human serum albumin. Biochem. Pharmacol. 48, 1693-1699 (1994).
23. J. C. Ojingwa, H. Spahn-Langguth, and L. Z. Benet: Reversible binding of tolmetin, zomepirac and their glucuronide conjugates to human serum albumin and plasma. J. Pharmacokinet. Biopharm. 22, 19-40 (1994).
24. A. Bischer, M. Iwaki, P. Zia-Amirhosseini, and L. Z. Benet: Stereoselective reversible binding properties of the glucuronide conjugates of fenoprofen enantiomers to human serum albumin. Drug Metab. Dispos. 23, 900-903 (1995).
25. N. Dubois, F. Lapicque, M.-H. Maurice, M. Pritchard, S. Fournel-Gigleux, J. Magdalou, M. Abiteboul, G. Siest, and P. Netter: In vitro irreversible binding of ketoprofen glucuronide to plasma proteins. Drug Metab. Dispos. 21, 617-623 (1993).
26. H. W. Ruelius, S. K. Kirkman, E. M. Young, and F. W. Janssen: Reactions of oxaprozin-1-0-acyl glucuronide in solutions of human plasma and albumin. Adv. Exp. Med. Biol. 197, 431-441 (1986).
27. C. Volland, H. Sun, J. Dammeyer, and L. Z. Benet: Stereoselective degradation of the fenoprofen acyl glucuronide enantiomers and irreversible binding to plasma protein. Drug Metab. Dispos. 19, 1080-1086 (1991).
28. B. C. Sallustio and D. J. R. Foster: Reactivity of gemfibrozil 1-O-β-acyl glucuronide. Pharmacokinetics of covalently bound gemfibrozil-protetn adducts in rats. Drug Metab. Dispos. 23, 892-899 (1995).
29. B. C. Sallustio and B. A. Fairchild: Biosynthesis, characterisation and direct high-performance liquid chromatographic analysis of gemfibrozil 1-O-β-acylglucuronide. J. Chromatogr. 665, 345-353 (1995).
30. W. W. Daniel (ed): "Biostatistics: A Foundation for Analysis in the Health Sciences." pp. 401-405. John Wiley and Sons. Inc., Toronto, Ontario, Canada, 1983.
31. L. Z. Benet, H. Spahn-Langguth, S. Iwakawa, C. Volland, T. Mizuma, S. Mayer, E. Mutschler, and E. T. Lin: Predictability of the covalent binding of acidic drugs in man. Life Sci. 53, PL141-PL146 (1993).
32. Y. Kurono, H. Sugiura, and K. Ikeda: Effects of drug binding on the esterase-like activity of human serum albumin. VI. Reaction with di-p-nitrophenyl adipate. Chem. Pharm. Bull. 33, 3966-3971 (1985).
33. Y. Kurono, Y. Ozeki, H. Yamada, T. Takeuchi, and K. Ikeda: Effects of drug bindings on the esterase-like activity of human serum albumin. VII. Subdivision of R-type drugs inhibiting the activity towards p-nitrophenyl acetate. Chem. Pharm. Bull. 35, 734-739 (1987).
34. Y. Kurono, A. Furukawa, T. Tsuji, and K. Ikeda: Esterase-like activity of human serum albumin. VI. Reaction with p-nitrophenyl glycinate. Chem. Pharm. Bull. 36, 4068-4074 (1988).
35. N. Dubois-Presle, F. Lapicque, M.-H. Maurice, S. Fournel-Gigleux, J. Magdalou, M. Abiteboul, G. Siest, and P. Netter: Stereoselective esterase activity of human serum albumin toward ketoprofen glucuronide. Mol. Pharmacol. 47, 647-653 (1995).
36. C. Lentner (ed): "Geigy Scientific Tables," vol. 3. pp. 135-162. Ciba-Geigy Ltd., Basel, Switzerland, 1984.
37. S. Worrall and R. G. Dickinson: Rat serum albumin modified by diflunisal acyl glucuronide is immunogenic in rats. Life Sci. 56, 1921-1930 (1995).
38. P. Zia-Amirhosseini, R. Z. Harris, F. M. Brodsky, and L. Z. Benet: Hypersensitivity to nonsteroidal anti-inflammatory drugs. Nature Med. 1, 2-4 (1995).